QNTM

QNTM

NASDAQ

Quantum BioPharma Ltd.

4.6

1.5(48.39%)
Volume

2.4M

Market Cap

$17.68M

P/E Ratio

-0.29

EPS

$-12.49


Price Chart

Price Alerts

No price alerts set. Add an alert to get notified!

Notify when price goes above $120.00
Notify when price goes above $180.00
Notify when price goes below $180.00

Key Financial Ratios

P/E Ratio

-0.29

P/B Ratio

0.36

EPS

$-12.49

ROE

-136.04%

Profit Margin

0.00%

Operating Margin

0.00%

Peer Comparison

Compare TSM with similar companies in the sector

Company Price Change % P/E Market Cap D/E
ANVS
Annovis Bio, Inc.
$2.40 -4.20% -2.06 $47.12M 0.00
ATNM
Actinium Pharmaceuticals, Inc.
$1.09 -4.82% -0.98 $33.85M 0.08
BCAB
BioAtla, Inc.
$0.15 -11.18% -0.14 $8.84M -0.20
CELU
Celularity Inc.
$1.28 5.79% -0.42 $30.79M -3.32
CPIX
Cumberland Pharmaceuticals Inc.
$3.18 4.26% -16.77 $47.56M 0.41
EVAX
Evaxion Biotech A/S
$3.63 -6.34% -3.01 $22.95M 0.44
PYPD
PolyPid Ltd.
$4.13 -0.48% -2.49 $42.09M 0.25
RMTI
Rockwell Medical, Inc.
$1.04 1.96% -6.79 $40.98M 0.35
RNTX
Rein Therapeutics Inc.
$1.22 2.10% -0.54 $31.94M 0.00
RVPH
Reviva Pharmaceuticals Holdings, Inc.
$0.83 -7.41% -0.13 $2.82M 0.00

* Peer stocks are selected based on market capitalization and sector

Private Notes

Key Statistics

52 Week High

$38.25

52 Week Low

$2.07

Dividend

$0.00

Dividend Yield

0.00%

About Quantum BioPharma Ltd.

Quantum BioPharma Ltd., a biopharmaceutical company, researches and develops a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development. The company operates through two segments, Biopharmaceutical and Strategic Investments. Its lead compound is Lucid-MS, a patented new chemical entity that is in Phase 2 clinical trial to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The company is also developing a treatment for alcohol misuse for application in hospitals and other medical practices. In addition, it maintains a portfolio of strategic investments comprising loans secured by residential property. The company was formerly known as FSD Pharma Inc. and changed its name to Quantum BioPharma Ltd., in August 2024. Quantum BioPharma Ltd., is headquartered in Toronto, Canada.